Skip to main content

Health Volunteer

0
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Suzhou Ribo Life Science Company
1 program
RBD5044PHASE_12 trials
Active Trials
NCT07587788Recruiting40Est. Mar 2027
NCT05539651Completed72Est. Oct 2024

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
Suzhou Ribo Life Science CompanyRBD5044
Suzhou Ribo Life Science CompanyRBD5044

Clinical Trials (2)

Total enrollment: 112 patients across 2 trials

RBD5044 in Chinese Participants With Hypertriglyceridemia

Start: Feb 2026Est. completion: Mar 202740 patients
Phase 2Recruiting

A Single and Multiple Ascending Doses Study to Evaluate the Safety and Pharmacokinetics of RBD5044

Start: Nov 2022Est. completion: Oct 202472 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 112 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.